BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 9, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 28, 2003
View Archived Issues
Spotlight on viral enzyme inhibitors for the treatment of chronic hepatitis B
Read More
Olprinone reduces gut mucosal injury in rabbit model of hypoxia
Read More
E-7389 analogues designed to have minimal susceptibility to P-glycoprotein-mediated drug efflux
Read More
FR-901228 induces apoptosis in primary and metastatic uveal melanoma cell lines
Read More
U. of Minnesota scientists claim new cADPR analogues for use as immunostimulants
Read More
AstraZeneca presents new MEK inhibitors in a recent patent
Read More
IOP-lowering agents prepared and tested by Alcon researchers
Read More
Novel lipase inhibitors for obesity and diabetes in early development at OSI
Read More
New NHE-3 inhibitors and their use in sleep apnea, renal failure, stroke, etc.
Read More
Taisho patents novel melanocortin MC4 receptor antagonists
Read More
Pfizer claims new 5-HT4 receptor modulators and their use in gastrointestinal disorders
Read More
Antitumor and antiinflammatory properties of synthetic triterpenoids under study at Dartmouth
Read More
Third-generation protease inhibitor active against wild-type and resistant HIV
Read More
Lead NPI-2350 (halimide) analogues with improved cytotoxic activity presented at AACR meeting
Read More
Preliminary 48-week data from CONTEXT study
Read More
CF-101 evaluated in new phase II trial for active RA
Read More
Pan-VEGFR tyrosine kinase inhibitor with antiangiogenic and antiproliferative activity
Read More
Phase II Canadian trial of MC-4232 cleared to begin
Read More
Positive phase II results for arginine deiminase in HCC support initiation of phase III trial
Read More
MBI-226 fails to meet primary endpoint in phase III trial
Read More
VNP-40101M in combination with AraC tested in new phase I trial for leukemia
Read More
La Jolla may seek accelerated approval for Riquent
Read More
Zyvox approved for diabetic foot infections
Read More
BTG licenses anxiety and depression compounds to Abiogen
Read More
FDA clears safinamide IND for Parkinson's disease
Read More
Enbrel becomes the first FDA-approved biologic for ankylosing spondylitis
Read More
